# miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial

> **NCT06285253** · PHASE1 · COMPLETED · sponsor: **Miromatrix Medical Inc.** · enrollment: 10 (actual)

## Conditions studied

- Acute Liver Failure
- Acute Liver Injury, Drug Induced
- Acute on Chronic Liver Failure (ACLF)
- Acute Alcoholic Hepatitis

## Interventions

- **COMBINATION_PRODUCT:** miroliverELAP treatment

## Key facts

- **NCT ID:** NCT06285253
- **Lead sponsor:** Miromatrix Medical Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-05
- **Primary completion:** 2026-01-22
- **Final completion:** 2026-01-22
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06285253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06285253, "miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06285253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*